O112 : HBsAg clearance after addition of 48 weeks of pegifn in HBeAg negative CHB patients on nucleos(T)ide therapy with undetectable hbvdna for at least one year: final results from ANRS-HB06 pegan study: multicenter randomized controlled phase III trial - Université de Rennes Access content directly
Conference Papers Year : 2015

O112 : HBsAg clearance after addition of 48 weeks of pegifn in HBeAg negative CHB patients on nucleos(T)ide therapy with undetectable hbvdna for at least one year: final results from ANRS-HB06 pegan study: multicenter randomized controlled phase III trial

Abstract

no abstract
No file

Dates and versions

hal-01162707 , version 1 (11-06-2015)

Identifiers

Cite

M. Bourlière, P. Rabiega, N. Ganne-Carrie, L. Serfaty, P. Marcellin, et al.. O112 : HBsAg clearance after addition of 48 weeks of pegifn in HBeAg negative CHB patients on nucleos(T)ide therapy with undetectable hbvdna for at least one year: final results from ANRS-HB06 pegan study: multicenter randomized controlled phase III trial. The International Liver Congress™ 2015 – 50th Annual meeting of the European Association for the Study of the Liver, Apr 2015, Vienne, Austria. pp.S249, ⟨10.1016/S0168-8278(15)30131-8⟩. ⟨hal-01162707⟩
243 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More